Lundbeck ready to take Genmab antibody to phase II
11 years after having entered into a partnership with Genmab about the antibody treatment for disease in the central nervous system, Lundbeck is now ready to start a phase II trial with a potential treatment for multiple system atrophy (MSA).
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY DANIEL PEDERSEN
After an 11-year collaboration, the Danish alliance between Genmab and Lundbeck has reached another clinical milestone, according to the database Clinical Trials, which collects information about research studies.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Genmab upgrades financial guidance again
For subscribers
